ETFs & MarketsPremiumMizuho Adjusts Nurix Valuation Following Roche Partnership
Mizuho has increased its price target for Nurix Therapeutics to $34 following a strategic collaboration agreement with Roche. This adjustment highlights the market's reaction to the clinical and commercial potential of the partnership.
Published 1 hour ago
Read more →